{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Ixabepilone",
  "nciThesaurus": {
    "casRegistry": "219989-84-1",
    "chebiId": "CHEBI:63605",
    "chemicalFormula": "C27H42N2O5S",
    "definition": "An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.",
    "fdaUniiCode": "K27005NP0A",
    "identifier": "C37452",
    "preferredName": "Ixabepilone",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C2584"
    ],
    "synonyms": [
      "(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione",
      "Azaepothilone B",
      "BMS 247550",
      "BMS-247550",
      "BMS247550",
      "Epothilone",
      "Epothilone-B BMS 247550",
      "IXABEPILONE",
      "Ixabepilone",
      "Ixempra",
      "ixabepilone"
    ]
  }
}